| abstract |
The present invention relates to compounds useful as inhibitors of Lysyl oxidase (LOX) and members of the LOXL family (LOXL1, LOXL2, LOXL3, LOXL4) of the Lysyl oxidase type. The invention also relates to pharmaceutical compositions comprising the compounds and the use of the compounds in the treatment of LOX and LOXL mediated disease states, for example cancer. In particular, an LOX inhibitor such as the compounds provided by the present invention may be for use in the treatment of cancer associated with EGFR. The present invention further relates to the identification of biomarkers for predicting reactivity to a LOX inhibitor. |